PureTech Health (LON:PRTC) Stock Price Down 12.4% – Here’s What Happened

Shares of PureTech Health plc (LON:PRTC) were down 12.4% during trading on Wednesday . The company traded as low as GBX 100.40 ($1.31) and last traded at GBX 103 ($1.35). Approximately 3,018,245 shares traded hands during mid-day trading, an increase of 192% from the average daily volume of 1,035,028 shares. The stock had previously closed at GBX 117.60 ($1.54).

Wall Street Analysts Forecast Growth

Separately, Jefferies Financial Group reissued a “buy” rating and set a GBX 455 ($5.96) price objective on shares of PureTech Health in a report on Monday, December 16th.

PureTech Health Price Performance

The stock has a market capitalization of £354.45 million, a P/E ratio of -4.84 and a beta of 1.02. The company has a debt-to-equity ratio of 45.82, a quick ratio of 2.51 and a current ratio of 3.68. The firm has a fifty day moving average price of GBX 135.24 and a two-hundred day moving average price of GBX 148.08.

PureTech Health Company Profile

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.